Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Vaccine
- Drug Discovery
- Cancer
- cell therapy
- Herpes
- Respiratory
- Delivery
- Immune
- Disease
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 308733
For the Exclusive License, the Licensor of Sweden grants an exclusive license, with the right to grant sublicense, under the Licensed Technology to import, make, have made, use, sell, offer for sale and otherwise exploit Licensed Products in the Exclusive Field in the Territory and otherwise exploit the Licensed Know-How in connection therewith.
For the Time-Limited Exclusive License, Licensor grants an exclusive, limited in time license, with the right to grant sublicenses, under the Licensed Technology to import, make, have made, use, sell, offer for sale and otherwise exploit Licensed Products in the Time-Limited Exclusive Field in the Territory and otherwise exploit the Licensed Know-How in connection therewith.
For the Non-Exclusive License, Licensor grants a nonexclusive license, with the right to grant sublicenses, under the Licensed Technology to import, make, have made, use, sell, offer for sale and otherwise exploit Licensed Products in the Non-Exclusive Field in the Territory and otherwise exploit the Licensed Know-How in connection therewith; provided, however, that with respect to the Joint Technology.
Licensee Antigen means any antigen (a) owned or otherwise Controlled by Licensee and (b) believed to trigger an immune response causing the production of antibodies and/or cytokine or T-cell responses in humans as a defense against or treatment for a Disease Field.
Licensed Adjuvant means an adjuvant Controlled by Licensor which incorporates or is developed from Matrix-A, Matrix-C and/or Matrix-M technology.
Licensed Product means any vaccine product containing both the Licensed Adjuvant and one or more Licensee Antigens; provided, however a Licensed Product may include a combination vaccine product for two or more Disease Fields but not a combination vaccine product for a Disease Field and a field that is not a Disease Field.
Matrix-A means a component of the Matrix M adjuvant that is produced by mixing together HPLC-purified fraction A from Quillaja saponin bark, cholesterol and phosphatidyl choline to form Iscom particles.
Matrix-C means a component of the Matrix M adjuvant that is produced by mixing together HPLC-purified fraction C from Quillaja saponin bark, cholesterol and phosphatidyl choline to form Iscom particles.
Matrix-M means a suspension of Matrix A and Matrix C particles that are combined in varying ratios of Matrix A to Matrix C.
The agreement grants Licensee license to two patent families, to import, make, have made, use, sell, offer for sale and otherwise exploit licensed vaccine products containing an adjuvant which incorporates or is developed from Matrix-A, Matrix-C and/or Matrix-M technology, in the fields of HSV and chlamydia, and the time-limited exclusive fields of Neisseria gonorrhoeae, cytomegalovirus, or CMV, and Mycobacterium tuberculosis.
Licensee is a clinical stage biotechnology company that discovers and develops novel vaccines to address infectious diseases for which no vaccine or vaccines with limited effectiveness exist today, using a proprietary discovery platform, ATLAS, to rapidly design vaccines that act through T cell (or cellular) immune responses, in contrast to approved vaccines, which are designed to act primarily through B cell (or antibody) immune responses. Licensee is also developing a second T cell vaccine candidate, GEN-004 for pneumococcus, a leading cause of infectious disease mortality worldwide.
IPSCIO Record ID: 368651
This agreement includes a non-exclusive grant back from Licensee to Licensor.
The Compound is designated by Licensor as Resiquimod (R-848), S36212, 1-(4-aminobutoxy) -2-butyl-lH-imidazo (4,5-cl quinolin-4-amine and conjugates thereof.
Product shall mean any combination of a Licensee Antigen Presenting Cell or APC Targeting Technology vaccine with a Licensed Compound to be utilized as a Vaccine Adjuvant.
Vaccine Adjuvant shall mean a Licensed Compound which is used to induce, augment, fine-tune, enhance, or desensitize an antigen-specific immune response to an antigen contained in a vaccine or generated by a DNA vaccine for the therapeutic treatment of an existing disease or prophylactic use as protection against future disease, including desensitization to allergens. The antigen and the vaccine adjuvant may be admixed, delivered simultaneously, conjugated, or delivered separately, provided however, that the separate administration of the antigen and vaccine adjuvant is limited to the topical, dermal or mucosal or intradermal routes of administration and must be administered within 48 hours at substantially the same site and labeled as such by the applicable regulatory authority.
TLR compounds, also called TLR7 and TLR8 agonists, are small organically synthesized molecules that offer flexibility in formulating and route of delivery, and ease in manufacturing, unlike most other TLR agonists, which are much larger and not as easy to manufacture.
The Field shall mean human prophylactic or therapeutic vaccination against any and all cancer disease states and selected infectious diseases.
This agreement focus is Cancer and the Infectious Diseases
– human immunodeficiency virus (HIV);
– human papillomavirus (HPV); and,
– hepatitis B virus (HBV).
IPSCIO Record ID: 308732
The College grants to Licensee a non-exclusive, worldwide, license under its rights in and to the College Technology Transfer Materials solely for use in identifying, discovering, developing, making, having made, using, marketing, offering for sale, selling, having sold and importing any Type I Licensed Product or Type II Licensed Product.
Type I Licensed Product shall mean any product, the manufacture, use, sale, marketing or importation of which falls within the scope of a Valid Claim in the country in which it is manufactured, used, sold, marketed or imported. Type II Licensed Product' shall mean any product that is not a Type I Licensed Product, but is identified or discovered through the use of a Licensed Method.
Licensed Services shall mean any service provided for or on behalf of a third party on a fee-for-service basis that entails the practice of a Licensed Method.
Materials transferred include
– Chlamydia libraries (donor library and expression library with and without cLLO)
– pDEST-SL8 expression vector
– Plasmids and E. Coli Strains
– T cell Lines
– Other Cell Lines, and,
– Protocols as follows
1. Gateway cloning
2. CE6 phage prep
3. Library induction
4. Library screening
5. Chlamydia growth and prep
6. T cell expansion (multiple protocols)
7. APC preps
8. Chlamydia infection ( cell line and mouse)
9. B3Z assay for library validation
10. ICS assay for antigen presentation
Chlamydia, or more specifically a chlamydia infection, is a sexually transmitted infection caused by the bacterium Chlamydia trachomatis.
Licensee is a clinical stage biotechnology company that discovers and develops novel vaccines to address infectious diseases for which no vaccine or vaccines with limited effectiveness exist today.
IPSCIO Record ID: 345562
ChAdOx1 and ChAdOx2 are modified simian adenoviral vectors which deliver target antigens into cells to generate a specific immune response. These viruses were originally isolated from chimpanzees to avoid pre-existing immunity issues affecting the use of human adenovirus vectors.
IPSCIO Record ID: 280952
For the Research Licenses, Licensor grants a world-wide, non-exclusive license, with the right to sublicense, under the Licensed Patents and Know-How, to use and import Licensed Adjuvant solely to conduct research for, or in respect of, the development of Products for use in the Field of Use for the Term.
Licensor grants the right to sublicense the rights granted herein.
For the Trademark License, Licensor grants a worldwide, royalty-free, nontransferable, non-exclusive license, during the term, to use and reproduce the Powered by Corixa trademark in the course of distributing, promoting and selling the Products solely for use within the Field of Use in the Territory.
Product means any pharmaceutical composition, comprising the Licensees Antigen and Licensed Adjuvant as an ingredient or component.
Licensees Antigen, BLP25 MUCl antigen, as such antigen may be improved, enhanced, or otherwise modified, as well as any other antigens that incorporate MUC 1.
